Render Target: SSR
Render Timestamp: 2024-11-14T22:48:35.170Z
Commit: 3c1f305a63297e594ac8d7bb5424007d592d68be
XML generation date: 2024-09-30 01:55:56.070
Product last modified at: 2024-10-17T14:15:12.474Z
1% for the planet logo
PDP - Template Name: Monoclonal Antibody
PDP - Template ID: *******c5e4b77
R Recombinant
Recombinant: Superior lot-to-lot consistency, continuous supply, and animal-free manufacturing.

IDH2 (D8E3B) Rabbit mAb #56439

Filter:
  • WB
  • IP
  • IHC

    Supporting Data

    REACTIVITY H M R
    SENSITIVITY Endogenous
    MW (kDa) 43
    Source/Isotype Rabbit IgG
    Application Key:
    • WB-Western Blotting 
    • IP-Immunoprecipitation 
    • IHC-Immunohistochemistry 
    Species Cross-Reactivity Key:
    • H-Human 
    • M-Mouse 
    • R-Rat 

    Product Information

    Product Usage Information

    Application Dilution
    Western Blotting 1:1000
    Immunoprecipitation 1:50
    Immunohistochemistry (Paraffin) 1:400 - 1:1600

    Storage

    Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody.

    For a carrier free (BSA and azide free) version of this product see product #35740.

    Protocol

    Specificity / Sensitivity

    IDH2 (D8E3B) Rabbit mAb recognizes endogenous levels of total IDH2 protein. This antibody does not cross-react with IDH1 protein. Species cross-reactivity for IHC-P is human only.

    Species Reactivity:

    Human, Mouse, Rat

    Source / Purification

    Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Val195 of human IDH2 protein.

    Background

    IDH2 is one of three isocitrate dehydrogenases (IDH1-3) that catalyze the oxidative decarboxylation of isocitrate to produce CO2 and α-ketoglutarate (α-KG). These enzymes belong to two distinct subclasses that utilize either NAD or NADP+ as an electron acceptor. IDH2 is an NADP+-dependent isocitrate dehydrogenase expressed primarily in the mitochondria, where it also functions in the TCA cycle (1,2). Mutations in IDH2 or its cytoplasmic counterpart (IDH1) have been reported in glioblastoma multiforme (3), acute myeloid leukemia (4,5), and other malignancies (6). Research studies have shown that gain-of-function mutations in IDH2 can lead to the accumulation and secretion of the oncometabolite R-2-hydroxyglutarate (2HG) in cancer cells (6,7).
    For Research Use Only. Not For Use In Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    SignalStain is a registered trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.